• Anti-InfectiveClosed to Enrollment

  Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis Extension Study , protocol number Novartis CTBM100C2401E1

  The purpose of this extension study is to collect additional safety data from patients taking TIP who have completed the core study "Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis".

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 75%

  • Number of Visits:

    8

  • Length of Participation:

    48 weeks

• ObservationalClosed to Enrollment

  Phase 4 TOBI Podhaler observational study , protocol number Novartis CTBM100C2407

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness and long term safety of the TOBI Podhaler and other FDA-approved inhaled antipseudomonal drugs.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 80%

  • Number of Visits:

    22

  • Length of Participation:

    60 months

• Anti-InfectiveCompleted with Results

  Tobramycin Inhalation Powder Compared to TOBI in People with CF , protocol number CTBM100C2302

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 75%

  • Number of Visits:

    11

  • Length of Participation:

    6 months

• Anti-InfectiveCompleted with Results

  Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered Twice a Day Cycled , protocol number NOVARTIS CTBM100CUS03

  This open-label study tested the effectiveness and safety of two different dose regimens of Tobramycin Inhalation Powder (TIP) for the treatment of Pseudomonas aeruginosa.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 80%

  • Number of Visits:

    9

  • Length of Participation:

    24 weeks

• Anti-InfectiveCompleted with Results

  Tobramycin Inhalation Powder (TIP) in People with Cystic Fibrosis , protocol number Novartis CTBM100C2401

  This open-label study assessed the long term safety of tobramycin inhalation powder (TIP) in people with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25 to 75%

  • Number of Visits:

    9

  • Length of Participation:

    52 weeks

• ObservationalCompleted with Results

  TOBI Podhaler Usability Study , protocol number Novartis CTBM100C2412

  This study evaluated how well people were able to understand and follow the TOBI Podhaler® instructions for use to achieve appropriate dosing.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    25% or greater

  • Number of Visits:

    2

  • Length of Participation:

    1 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.